Introduction
Inflammatory, infectious, and neoplastic disorders encompass the majority of dermatologic conditions and are all characterized by excess vascularity, suggesting that many common skin disorders are potentially amenable to antiangiogenic therapy (Arbiser, 1996 (Arbiser, , 1997b . The endothelial cell is the prime effector of angiogenesis and outside of embryogenesis, it has two potential origins. One is local recruitment of endothelial cells from local mesenchymal cells, and the other is recruitment and transdifferentiation of endothelial cells derived from bone marrow stem cells (Arbiser et al., 1998a; Moore et al., 2001) . In Since the 17th century, anatomists have recognized the importance of blood vessels. The discovery of lymphatics in dogs by Aselli in 1622, followed by their discovery in man by Pequet in 1647, added to our awareness a second circulatory system of clear importance. John Hunter is credited with first noting ''angiogenesis'' in 1794 by recognizing the development of growing vessels in healing wounds. In his Nobel-winning work of the early 20th century, August Krogh demonstrated the dynamic nature of blood vessels; he associated increased capillary density and increased metabolic requirements. In 1941, Greene et al. demonstrated that the growth of tumors transplanted into the anterior chamber of the eye occurred coincidental with the growth of new blood vessels. The importance of angiogenesis was further advanced by the work of Judah Folkman in the 1960s, who suggested that inhibiting the growth of blood vessels might inhibit tumor growth. The development of new molecular markers has recently allowed rapid growth in our understanding of the role these vessels play in normal tissue and in cancer. In this issue of the JID, Drs Arbiser and Detmar present an update on angiogenesis and lymphogenesis in the skin and the critical role these vessels play in cancer, wound healing, and tissue remodeling. advanced malignancy, tumor cells may phenotypically resemble endothelial cells and form vascular channels, a process termed vascular mimicry (Hess et al., 2001) . A pathologic process may recruit endothelial cells from either or both of these sources, and the efficacy of angiogenesis inhibitors may depend on the source of endothelial cells from a lesion (Benezra et al., 2001; Rafii et al., 2001; Li et al., 2004) .
A major concept in the development of angiogenesis inhibitors is the recognition of an angiogenic switch (Folkman et al., 1989; Hanahan and Folkman, 1996) , which means that a given cell produces both angiogenesis stimulators and direct or indirect inhibitors of angiogenesis (Arbiser et al., 1997; Klafter and Arbiser, 2000) . As a cell becomes more malignant, the relative balance between angiogenesis stimulators and inhibitors tilts in favor of angiogenesis stimulators. Direct inhibitors are agents that inhibit endothelial cell function and prevent the development of a neovasculature. Indirect inhibitors act on cells that produce angiogenesis stimulators such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and corticotrophin releasing factor, and impair their ability to promote angiogenesis (Arbiser, 1997a; Arbiser et al., 1998a, b) .
Finally, there are multiple regulators of production of angiogenesis stimulators and inhibitors. Probably the best studied is the regulation of VEGF. VEGF is regulated by several stimuli, including reactive oxygen, hypoglycemia, and hypoxia (Shweiki et al., 1995; Forsythe et al., 1996; Arbiser, 2003; Cerimele et al., 2005) . The most well known is hypoxia, or low oxygen tension, which is present in many solid tumors. Hypoxia induces transcription and stability of hypoxia-inducible factor 1 (HIF1), which is a heterodimer encoding HIF1a and HIF1b proteins, and potently induces VEGF transcription. The discovery that HIF-deficient cells are capable of forming aggressive tumors also implicates HIF-independent processes in VEGF upregulation (Carmeliet et al., 1998; Acker et al., 2005) . Although development of HIF inhibitors is currently an active area of research, recognizing that tumor cells are capable of switching use of signaling pathways, and treating of tumors with HIF inhibitors will likely select for tumors that use HIF-independent pathways in tumor development.
Dual Origins of Endothelium
Endothelial cells are mesenchymal cells that are capable of long durations of quiescence, but may migrate, invade, and form lumens upon an angiogenic stimulus. Endothelial cells express a variety of adhesion molecules that cause adhesion of immune effector cells that migrate to sites of infection or inflammation. Exposure to cytokines or direct endothelial infection by pathogens leads to upregulation of endothelial adhesion molecules (Cerimele et al., 2003) .
After observing that both tumors and the immediately adjacent non-neoplastic tissue are highly vascularized, Folkman described the concept of local recruitment of endothelial cells by elaboration of factors by tumor cells. This was elegantly illustrated by the observation that implantation of V2 rabbit squamous cell carcinoma into the avascular rabbit cornea led to the development of a neovasculature in the normally avascular cornea (Gimbrone et al., 1972) . This observation, along with the ability to culture microvascular endothelium in vitro led to the discovery of the first angiogenesis factor, basic fibroblast growth factor. Subsequently, several factors have been shown to contribute to angiogenesis though activation of tyrosine kinase receptors present on endothelium such as fibroblast growth factor receptor, vascular endothelial growth factor receptor 2 (VEGFR2), hepatocyte growth factor receptor, IL-4 receptor, IL-6 receptor, as well as endothelial G protein receptors (corticotropin-releasing hormone receptors, leptin receptors, and Kaposi G protein-coupled receptor).
The recognition that circulating endothelial precursors are present in humans was made by Isner's group, who demonstrated that cells derived from human buffy coats (fractions of human blood centrifuged to enrich for leukocytes) could be differentiated into cells that express endothelial markers, including VEGFR1 and VEGFR2, as well as the endothelial marker CD31 (Asahara et al., 1997). Factors like angiopoietin 2 (ang2) may serve as chemoattractants for circulating endothelial progenitor cells (Gill and Brindle, 2005) .
Further evidence for the function of endothelial stem cells was the discovery of a functional role of VEGFR1 in angiogenesis. Although VEGFR2 has been shown to participate in a wide variety of signaling functions of endothelial cells, the function of VEGFR1 was not well understood. A particularly thorny issue was the fact that a VEGFR1 knockout is embryonic lethal in mice, whereas a partial knockout of the transmembrane portion of VEGFR1 has little effect on phenotype. Studies have shown that neutralizing antibodies to VEGFR1 have antiangiogenic activities, and that combination of VEGFR1 blockade with VEGFR2 blockade has potent antiangiogenic activity in mouse models . Finally, a mouse that was a combined knockout of transcription factors Id1 and heterozygous for the related factor Id3 was relatively resistant to tumor formation caused by injection of wellknown tumor cells into these mice (Lyden et al., 1999; Rafii et al., 2002) . The ability to form tumors in these mice could be restored by the transplantation of wild-type bone marrow, suggesting a bone marrow element contributing to tumor neovascularization. Further experimentation with these knockout mice demonstrated that although they were relatively resistant to tumor formation by injection of tumor cells, they were not resistant to tumors caused by carcinogenesis. One likely explanation is that local recruitment may play a role in the early development of tumors, and tumors may gain the ability to recruit bone marrow cells with advanced growth.
These findings may explain several observations in experimental cancer therapy. First, a large group of natural products, collectively known as chemopreventive agents, are effective in the prevention of tumors, yet have little efficacy in the treatment of advanced tumors (Arbiser et al., 1998c; Gupta et al., 2003) . Conversely, the use of advanced tumor xenograft models to provide proof of principle for angiogenesis inhibition may select for agents that inhibit stem cell recruitment, but may not prevent local recruitment by the tumor itself. Inhibition of tumor growth may require attenuation of both of these processes, along with recognition that blockade of only one of those pathways will likely lead to resistance through cooperation of the other pathway (Figure 1) .
Several of the major ligands for endothelial recruitment and their functional role in revascularization of ischemic tissue have been established in murine models. Stromal cell-derived factor-1 and stem cell factor are expressed in endothelial tumors and signal through CXCR4 and c-kit receptors, respectively (Nadiminiti et al., 2005) . Blockade of CXCR4 with small molecule antagonists has been shown to block revascularization of ischemic muscle. Stromal cell-derived factor-1 has been demonstrated in epithelial malignancies including ovarian cancer (Porcile et al., 2005) . Other factors involved in stem cell recruitment include thrombopoietin and soluble kit ligand . Thrombopoietin signals through a receptor c-mpl, which is present on both platelet precursors and endothelial stem cells. Soluble kit ligand is a potent mobilizing factor for endothelial stem cells, and is released from cell surfaces by matrix metalloproteinase-9. Mice deficient in matrix metalloproteinase-9 fail to mobilize soluble kit ligand, and thus have deficiencies in stem cell mobilization. Mobilization of stem cells may potentially cause revascularization of ischemic tissue, and may have clinical utility in the treatment of acute myocardial infarction (Orlic et al., 2001) .
Defects in stem cell recruitment may take place at levels other than mobilization. Recently, cathepsin L has been shown to be critical for invasion of endothelial stem cells into target tissues, and mice deficient in cathepsin L develop a dilated cardiomyopathy, possibly due to the failure of stem cells to repopulate the heart (Stypmann et al., 2002; Urbich et al., 2005) . The transcription factor Hox A9 is also highly expressed in endothelial stem cells, and Hox A9 knockout mice, although born viable, are deficient in endothelial stem cells, and are deficient in clonal expansion of endothelial precursors from bone marrow which leads to defective stem cell recruitment (Lawrence et al., 1997; Bruhl et al., 2004) .
Recognition of the dual origins of endothelial cells may provide the pathologist and clinician with markers to identify and therapeutically target the source of aberrant (or pathologic) endothelial cells. One potential marker of stem cell recruitment is the angiogenic protein angiopoietin-2 (ang2), which was initially discovered as an antagonist to ang1. Although both bind to the same receptor, tie-2, ang1 blocks vascular permeability, but ang2 stimulates it (Figure 2 ). This may occur through crosstalk between tie-2 and VEGFR2, or even heterodimerization (Scharpfenecker et al., 2005) Figure 1 . Tumors recruit endothelial precursor cells through multiple ligands. Tumor cells produce numerous chemokines, such as ang-2, stromal cell-derived factor-1, and soluble kit ligand. Soluble kit ligand is generated from cell membranes by the activity of matrix metalloproteinase-9. Endothelial precursors required Hox A9 for survival and growth, as well as cathepsin L for migration from bone marrow to the site of tumors.
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Tie-2 Tie-2 Figure 2 . Paradox of opposing activities of ang-1 and ang-2. Both ang-1 and ang-2 act at the tie-2 receptor, and stimulate phosphoinositol 3 kinase/akt signaling. However, ang-1 stabilizes endothelium and inhibits vascular permeability, whereas ang-2 destabilizes endothelium and increases vascular permeability. Ang-2 may act by not only stimulating phosphoinositol 3 kinase/akt, but also by inducing reactive oxygen. This may occur at the level of crosstalk or even heterodimerization.
1999; Pomyje et al., 2001; Hu et al., 2003; Hata et al., 2004) . Interestingly, both hemangiomas of infancy and verruga peruana, a hemangioma-like tumor caused by endothelial infection from Bartonella bacilliformis, have elevated expression of ang2 (Yu et al., 2001; Cerimele et al., 2003) . Experimental models of hemangiomas also express stem cell factor, consistent with current theories of hemangiomas being derived from stem cells (Meininger et al., 1995) . We have demonstrated that treatment of mice carrying polyoma middle T-expressing endothelium with a soluble tie-2 causes inhibition of hemangioma growth in vivo, suggesting a functional role of ang2 in hemangioma growth in vivo (Govindarajan and Arbiser, unpublished data). Hemangiomas also express a number of stem cell markers including AC133, (Yu et al., 2004) suggesting they originate from endothelial stem cells. Thus, it is likely that hemangiomas arise from an unknown event which causes rapid recruitment of endothelial stem cells from the bone marrow, and that a similar process may contribute to angiogenesis in highly malignant tumors. Involution is an important property of normal neoangiogenic vessels and upon withdrawal of the stimulus, a neovasculature will undergo regression through apoptosis. This is seen physiologically in both the female menstrual cycle, where endothelial cells undergo apoptosis upon withdrawal of estrogen and in the regression phase of hemangiomas of infancy. Persistence of endothelium is physiologically maintained through recruitment and investment by layers of smooth muscle. Pathologic persistence of endothelium is maintained by excessive stimulation of angiogenic growth factors, loss of endogenous factors, or mutations that cause endothelial cells to resist physiologic apoptosis (Levchenko et al., 2004) . These mutations, many of which activate the phosphoinositol-3 kinase/ akt pathway, account for vascular malformations in humans. They may occur in a tissue-specific fashion, such as hereditary hemorrhagic telangiectasia, with defects in the skin, gastrointestinal, and liver vessels, or cerebral cavernous hemangioma, which is a brain-specific cavernous malformation syndrome. These mutations may lead to abnormal persistence of vessels, possibly through abnormal activation of b1 integrin or constitutive activation of antiapoptotic molecules such as akt.
We have recently found that Wilms tumor 1 is present in angiogenic vessels capable of regression, such as hemangiomas, but not in vascular malformations (Lawley et al., 2005) . Wilms tumor 1 is a transcription factor that was initially found to be deficient in hereditary Wilms tumor, but is also activated in numerous hematopoietic malignancies. Recently, Wilms tumor 1 has also been found in the cytoplasm of cell as well, where it is implicated in selective protein translation (Pritchardjones et al., 1990; Schedl and Hastie, 1998) . One possibility is that additional factors such as placenta growth factor stabilize vessels through downregulation of Wilms tumor 1 and endogenous angiogenesis inhibitors such as IFN-a, thrombospondins 1 and 2, endostatin, and angiostatin, thereby preventing regression . Placenta growth factor knockout mice are viable and fertile, but show increased resistance to experimental carcinogenesis.
Inflammatory Angiogenesis
Inflammatory skin conditions comprise a wide variety of conditions, including psoriasis, atopic dermatitis/eczema, lupus, and dermatomyositis. These conditions are classified as Th1 if they have a predominance of cytokines such as IFN-g, IL-12, IP-10, or Th2 if associated with ILs 4, 5, 6, and 10. Both Th1-and Th2-mediated inflammation have common features, including deficient epidermal barrier function, inflammatory infiltrates of lymphocytes, mast cells, granulocytes, and macrophage/monocytes. Histologically, Th2 inflammation is associated with high levels of eosinophils and B-cell proliferation. Despite the differential expression of cytokines, both Th1-and Th2-mediated inflammation demonstrate excess angiogenesis, suggesting antiangiogenic therapies may have utility in the treatment of a broad variety of skin disorders.
Tumor necrosis factor-alpha (TNF-a) is a major cytokine required for maintenance of a variety of T cell-mediated autoimmune disorders and exhibits a duality of action. As its name implies, TNF-a has antitumor activity in some systems, and loss of its activity is associated with increased carcinogenesis in some systems. The clinical observation that certain tumors disappeared in the presence of infection (Cooley's toxin) led to the eventual discovery of TNF-a, along with the hope that TNF could be used therapeutically. Alternatively, chronic inflammatory conditions such as inflammatory bowel disease, schistosomiasisassociated bladder cancer, hidradenitis suppurativa, and viral hepatitis, are associated with high levels of TNF-a. These conditions are also carcinogenic, thus making it likely that malignancies that arise in an inflammatory milieu are resistant to TNF-a. How can one explain this duality (Arbiser, 2004a) ? TNF-a is associated with high levels of reactive oxygen, which may either kill tumor cells or serve as a tumor promoter. Tumors that have intact mitochondrial activated caspases, like caspase 3, 9, and apaf-1 are highly sensitive to reactive oxygen-mediated cell killing, such as by TNF-a, bleomycin, and X irradiation. Reactive oxygen exerts its carcinogenic effects by silencing expression of tumor suppressor genes such as p16ink4a by hypermethylation, which appears to be a hallmark of reactive oxygen-induced carcinogenesis (Govindarajan et al., 2002) . Tumors arising in a milieu of reactive oxygen also inactivate mitochondrial caspase genes such as caspase 9 and apaf-1, commonly through methylation. One might predict that tumors caused by reactive oxygen would exhibit relative resistance to TNF-a-mediated killing, and in this setting, TNF-a may serve as a proangiogenic factor. The antiapoptotic akt family is critical in mediating resistance to reactive oxygen, and tumor cells that arise in the presence of reactive oxygen likely utilize akt for antitumor defenses (Figure 3) .
Conversely, a subset of tumors including many non-melanoma skin cancers is highly sensitive to both TNF-a and reactive oxygen. These tumors may be readily killed by TNF-a and demonstrate sensitivity to radiation therapy and bleomycin, which generates reactive oxygen. The increased use of TNF-a blockers such as remicade (infliximab) or enbrel (etanercept) for inflammatory disorders may lead to an increase in tumors that are susceptible to TNF-a, but are allowed to arise owing to blockade of TNF-a (Figure 3 ).
Dual Regulation of VEGF Production by Tumor Cells
VEGF is one of the most important tumor angiogenic factors, and is regulated by a number of conditions that in sum provide adequate perfusion of the tumor. These conditions include hypoxia, hypoglycemia, and reactive oxygen. In addition, oncogenes that are involved in transformation also increase baseline levels of VEGF, which then synergize with ambient conditions to upregulate VEGF.
The most well-characterized regulator of VEGF is hypoxia. Hypoxia induces the transcription factor HIF1a, which forms a heterodimer with aryl hydrocarbon nuclear translocator. The stability of HIF1a is closely regulated by the von Hippel-Lindau complex, which under conditions of normoxia, cause proteasomal degradation of HIF1a. When von Hippel Lindau is mutated or deleted, as in the disease von Hippel-Lindau syndrome, VEGF production is constitutively upregulated, as if the tumor cells are experiencing hypoxia even if they are not hypoxic.
Recent findings have shown that HIF1a is not required for tumor angiogenesis. Embryonic stem cells derived from HIF1a À/À mice are capable of forming teratomas that are more aggressive than wild-type mice. Another factor, HIF2a, has recently been discovered that has sequence similarity and aryl hydrocarbon nuclear translocator/HIF1b binding, but has otherwise potentially different findings. Knockin experiments of HIF2a into the HIF1a locus results in more aggressive tumors than mice that have native HIF1a expression (Kotch et al., 1999; Covello et al., 2005) .
Reactive oxygen species have also been implicated in sensing oxygen. Stabilization of HIF1a was observed in fibroblasts deficient in oxidative phosphorylation, demonstrating that intact oxidative phosphorylation is not required for HIF stabilization. However, blockade of electron transport through inhibition of complex III, or downstream blockade of p38 mitogen-activated protein kinase, which is activated by mitochondrially derived reactive oxygen (Brunelle et al., 2005; Emerling et al., 2005; Guzy et al., 2005) prevents HIF stabilization. Interestingly, hydrogen peroxide, but not superoxide, is required for stabilization of HIF, because elimination of hydrogen peroxide with glutathione peroxidase or catalase causes abrogation of HIF stabilization (Figure 4) . Our initial studies of tumorigenesis by nox genes, which generate both superoxide and hydrogen peroxide, neutralization of hydrogen peroxide resulted in decreased VEGF production, whereas neutralization of superoxide resulted in decreased production of matrix metalloproteinases (Arbiser et al., 2002) . In a platelet-derived growth factor-induced tumorigenesis model system of human cells, we observed that tumorigenesis was associated with high levels of hydrogen peroxide production, as well as high levels of VEGF mRNA (Govindarajan et al., 2005) . Finally, introduction of superoxide dismutase into melanoma cells abrogated its growth in vivo, supporting the use of reactive oxygen inhibitors such as disulfaram, ebselen, and honokiol for melanoma treatment (Church et al., 1993; Brar et al., 2004) .
The recognition of duality of angiogenesis has implications in the treatment of inflammatory and neoplasic disease. Our previous studies have shown that tumor cells can rapidly adapt to alterations in signaling without generating mutations, yet, still retain angiogenic capabilities. This poorly recognized fact argues for the use of combined or sequential therapies for the treatment of cancer. We have also found patterns of signaling that correlate with the tumor suppressor profile of a cancer, and that these patterns hold true for multiple forms of cancer (Arbiser, 2004b) . Finally, the recognition of multiple sources of endothelium will allow tailoring of antiangiogenic therapy, with the recognition that tumors that have high levels of superoxide may produce angiogenic factors that recruit endothelial precursors (Figure 4) , and that combined blockade of multiple forms of reactive oxygen may be necessary to prevent production of angiogenic factors by tumors. This knowledge will allow optimal use of VEGF blockade, such as bevacizumab (avastin), in combination with blockade of VEGF production (STI 517, COX-2 inhibitors, erlotinib, trastuzumab) and blockade of VEGF receptor activity . Low doses of oral chemotherapy agents have already been used in clinical medicine as angiogenesis inhibitors, with impressive results in brain tumors (Kieran et al., 2005) . Recently, avastin, a VEGF antibody, and pegaptanib, an RNA species that binds VEGF protein (aptamer), have been FDA approved for cancer and macular degeneration, respectively. Avastin prolongs survival in renal cell carcinoma, and in colon cancer when combined with chemotherapy (Gragoudas et al., 2004; Hurwitz et al., 2004; Ferrara et al., 2005; Ferrara, 2005) . The partial responses to these agents in colon and renal cell carcinoma reveal the promise of antiangiogenic therapy for solid tumors, yet point out that a single form of angiogenesis blockade is insufficient to destroy a solid tumor. Side effects of VEGF blockade in humans include hypertension and thrombosis, which are likely due to decreased nitric oxide production as a downstream event of VEGF blockade. It remains to be seen whether antihypertensives or anticoagulants affect the clinical efficacy of VEGF blockade. Multiple forms of angiogenesis blockade, along with strategies that block the metabolic advantages that tumors have, will be required for cures of solid tumors.
